Clinical Trial Update: Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tirabrutinib and idelalisib with/without obinutuzumab in relapsed/refractory chronic lymphocytic leukemia has completed and posted resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Idelalisib (idelalisib)
• Obinutuzumab (obinutuzumab)
• Tirabrutinib (tirabrutinib)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2020-07-01